<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 12/17/2022 3:26:58 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 2eb35821-7636-4106-b2d5-9c59a0387360 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:fbio="http://www.fortressbiotech.com/20221214" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityCentralIndexKey" id="Tc_tZxFMFh8l0qEEX4usog3Dw_1_1">0001429260</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:AmendmentFlag" id="Tc_32QnUujzH0ydu5teTMb-Rw_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fbio-20221214.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_12_14_2022_To_12_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_YkKt5REj7kO8C89rL8zzTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001429260</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_14_2022_To_12_14_2022_us-gaap_StatementClassOfStockAxis_fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember_Ur9cHArP2kyvhAyW2DldSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001429260</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001429260</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_83c04d94_e632_4ebf_98b2_c4dd433d1cb9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:DocumentType" id="Narr_Uf4y3-m8Ukeg7CzYZDRtfQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Pursuant to Sections&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:DocumentPeriodEndDate" id="Narr_bPHYCjV-ckqzizi8JC5TdA">December 14, 2022</ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityRegistrantName" id="Narr___Z-1pPRNEaK3vabztqFJg"><b style="font-weight:bold;">Fortress Biotech,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:32.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:31.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityIncorporationStateCountryCode" id="Narr_unUsF2EZMkuyFU4R7lMvMg"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b>(State or other jurisdiction<br />of incorporation)</p></td><td style="vertical-align:bottom;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:32.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityFileNumber" id="Narr_aUpg3ck65keUWPHf1w_QiQ"><b style="font-weight:bold;">001-35366</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b>(Commission File Number)</p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:31.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityTaxIdentificationNumber" id="Narr_QBu0wnWS00mbs6OBhOoFrw"><b style="font-weight:bold;">20-5157386</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b>(I.R.S. Employer<br />Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityAddressAddressLine1" id="Narr_GTfJtowoC0usdy9pN39eFg"><b style="font-weight:bold;">1111 Kane Concourse</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityAddressAddressLine2" id="Narr_Ij-AYchAMU2BOswptoMJZg"><b style="font-weight:bold;">Suite 301</b></ix:nonNumeric><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityAddressCityOrTown" id="Narr_oUzGOhu_6kCsWXHSUKFbug"><b style="font-weight:bold;">Bay Harbor Islands</b></ix:nonNumeric><b style="font-weight:bold;">,&#160;</b><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityAddressStateOrProvince" id="Narr_OY0O46qJ_0WOSL6JKHjEVg"><b style="font-weight:bold;">FL</b></ix:nonNumeric><b style="font-weight:bold;">&#160;</b><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityAddressPostalZipCode" id="Narr_juWwtcnaqk6RC5h_tDVcJw"><b style="font-weight:bold;">33154</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Registrant&#8217;s telephone number, including area code: <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:CityAreaCode" id="Narr_9w0abX6lVUS__u-hKMTiyA"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">781</b></ix:nonNumeric><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)&#160;</b><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:LocalPhoneNumber" id="Narr_XE1GdnvtWka9ZEGgoBUSNw"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">652-4500</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:WrittenCommunications" id="Narr_6OGUaXtzm0exNHUEv8bVgg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:SolicitingMaterial" id="Narr_2ZA7L2j6xkaVwbCNhOxNpg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:PreCommencementTenderOffer" id="Narr_l3IIgstw1E293W8jnZcmcg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;width:36pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:PreCommencementIssuerTenderOffer" id="Narr_1V7rcOODfUa6pVfNVZsklA"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 9pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter)</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_12_14_2022_To_12_14_2022_XZAblH7vIEeEN6k8RKLwfw" name="dei:EntityEmergingGrowthCompany" id="Narr_z-Ir1g1GSkmIyEdSDBeIFQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;text-align:justify;">Emerging growth company</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_64d2fc65_ac67_4124_a33d_effaec75c6b4"></a><a id="Tc_IVQ5-mren02rykocnioS6g_1_0"></a><a id="Tc_6rugYuWt1Uego1_cDf8Aqw_2_0"></a><a id="Tc_2MR2KbzFS0K5dqOnvCUXDw_2_1"></a><a id="Tc_iNgzwux5fEe4aeAnmck_XQ_2_2"></a><a id="Tc_nVBissa4lEeotz0gONpjkw_3_2"></a><a id="Tc_MJxkdkQFqU6nroyYXoo-_A_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:38.27%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:21.74%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:39.98%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p></td></tr><tr><td style="vertical-align:top;width:38.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:21.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:39.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:middle;width:38.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_YkKt5REj7kO8C89rL8zzTQ" name="dei:Security12bTitle" id="Tc_ObTqbqOunkG_zDEZ8vWcug_3_0">Common Stock</ix:nonNumeric></p></td><td style="vertical-align:middle;width:21.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_YkKt5REj7kO8C89rL8zzTQ" name="dei:TradingSymbol" id="Tc_pskoprn-jkK7Yr5SG454pQ_3_1">FBIO</ix:nonNumeric></p></td><td style="vertical-align:middle;width:39.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_12_14_2022_To_12_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_YkKt5REj7kO8C89rL8zzTQ" name="dei:SecurityExchangeName" id="Narr_y9l4dAqe60CSQVXhpl4gtQ">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr><tr><td style="vertical-align:middle;width:38.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_us-gaap_StatementClassOfStockAxis_fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember_Ur9cHArP2kyvhAyW2DldSA" name="dei:Security12bTitle" id="Tc_86vP19IdNke-6ovcUhhe9w_4_0">9.375% Series A Cumulative Redeemable Perpetual Preferred Stock</ix:nonNumeric></p></td><td style="vertical-align:middle;width:21.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_14_2022_To_12_14_2022_us-gaap_StatementClassOfStockAxis_fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember_Ur9cHArP2kyvhAyW2DldSA" name="dei:TradingSymbol" id="Tc_O6l75Ft7-kKuKnk5AR5r9Q_4_1">FBIOP</ix:nonNumeric></p></td><td style="vertical-align:middle;width:39.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 1.25pt 1.5pt 1.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_12_14_2022_To_12_14_2022_us-gaap_StatementClassOfStockAxis_fbio_SeriesCumulativeRedeemablePerpetualPreferredStockMember_Ur9cHArP2kyvhAyW2DldSA" name="dei:SecurityExchangeName" id="Narr_PgGAuFgQqkOqobz7aJsQHg">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_010f58a7_b15b_4e0e_a650_fd9e1da48118"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1.01 &#160;Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 14, 2022, Fortress Biotech, Inc. (the &#8220;Company&#8221;) entered into an indemnification agreement (the &#8220;Indemnification Agreement&#8221;) with Lucy Lu, M.D., substantially similar to the Company&#8217;s standard form of officer and director indemnification agreement. The Indemnification Agreement provides for the indemnification of directors to the fullest extent permitted by Delaware law and the Company&#8217;s Bylaws for claims brought against them relating to their service on behalf of the Company, the advancement of expenses in connection with any such claim, and the process for seeking indemnification and the advancement of expenses. The form of Indemnification Agreement between Ms. Lu and the Company is attached as Exhibit 10.1 to this report and is incorporated by reference to this Item 1.01, and the foregoing description is qualified in its entirety by the provisions of the form of the Indemnification Agreement.</p><a id="_2c658c49_bd08_4f2b_9762_a07cd7d707c5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 14, 2022, the Board of Directors (the &#8220;Board&#8221;) of the &#8220;Company elected Lucy Lu, M.D. as a new member of the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dr. Lu previously served as the Executive Vice President and Chief Financial Officer of the Company from February 2012 to June 2017 and the President and Chief Executive Officer of the Company&#8217;s subsidiary Avenue Therapeutics, Inc. (&#8220;Avenue&#8221;) from July 2017 until March 2022. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. Additionally, Dr. Lu has served as a member of the Board of Directors of Veru, Inc. since 2021, a position she also held from 2016 to 2018, and has served as a member of the Board of Directors of Iventiva Healthcare Limited since 2018. From February 2007 through January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of the firm in February 2006. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee&#8217;s College of Arts and Science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no arrangements or understandings between Ms. Lu and any other person pursuant to which she was elected as a director. Ms. Lu will receive compensation based on the same policies as the Company&#8217;s other non-employee directors, which are described in the Company&#8217;s definitive proxy statement filed with the SEC on May 2, 2022. In her role as Chief Executive Officer of Avenue, Ms. Lu received $1,082,129 in total compensation in 2021 and $1,052,962.17 in 2022. A press release related to Dr. Lu&#8217;s appointment is attached as Exhibit 99.1 to this report and is incorporated by reference to this Item 5.02.</p><a id="_ea5f7308_f3ac_499b_95ef_c5981ce73e18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statements and Exhibits. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(d) Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following exhibit is furnished herewith:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:9.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:88.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="fbio-20221214xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement (Lucy Lu)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="fbio-20221214xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release issued by Fortress Biotech, Inc., dated December 19, 2022.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are imbedded in the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fortress Biotech,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Registrant)</p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: December 19, 2022</p></td><td colspan="2" style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/&#160;Lindsay&#160;A.&#160;Rosenwald,&#160;M.D.</p></td></tr><tr><td style="vertical-align:bottom;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:46.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lindsay A. Rosenwald, M.D.</p></td></tr><tr><td style="vertical-align:bottom;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:46.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman, President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "fbio-20221214x8k.htm", "description": "8-K", "secsgml_size_bytes": 40666}]
{"company-data": {"conformed-name": "Fortress Biotech, Inc.", "cik": "0001429260", "assigned-sic": "2834", "irs-number": "205157386", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35366", "film-number": "221469665"}, "business-address": {"street1": "1111 KANE CONCOURSE", "street2": "SUITE 301", "city": "BAY HARBOR ISLANDS", "state": "FL", "zip": "33154", "phone": "781-652-4500"}, "mail-address": {"street1": "1111 KANE CONCOURSE", "street2": "SUITE 301", "city": "BAY HARBOR ISLANDS", "state": "FL", "zip": "33154"}, "former-company": {"former-conformed-name": "CORONADO BIOSCIENCES INC", "date-changed": "20080310"}}
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934
​
Date of Report (Date of earliest event reported):
December 14, 2022
Fortress Biotech, Inc.
(Exact name of registrant as specified in its charter)
​
Delaware
(State or other jurisdiction
of incorporation)
001-35366
(Commission File Number)
20-5157386
(I.R.S. Employer
Identification No.)
​
1111 Kane Concourse
,
Suite 301
Bay Harbor Islands
,
FL
33154
(Address of principal executive offices)
Registrant's telephone number, including area code:
(
781
)
652-4500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act
​
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
FBIO
Nasdaq
Capital Market
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
FBIOP
Nasdaq
Capital Market
​
​
​
Item 1.01  Entry into a Material Definitive Agreement.
On December 14, 2022, Fortress Biotech, Inc. (the "Company") entered into an indemnification agreement (the "Indemnification Agreement") with Lucy Lu, M.D., substantially similar to the Company's standard form of officer and director indemnification agreement. The Indemnification Agreement provides for the indemnification of directors to the fullest extent permitted by Delaware law and the Company's Bylaws for claims brought against them relating to their service on behalf of the Company, the advancement of expenses in connection with any such claim, and the process for seeking indemnification and the advancement of expenses. The form of Indemnification Agreement between Ms. Lu and the Company is attached as Exhibit 10.1 to this report and is incorporated by reference to this Item 1.01, and the foregoing description is qualified in its entirety by the provisions of the form of the Indemnification Agreement.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 14, 2022, the Board of Directors (the "Board") of the "Company elected Lucy Lu, M.D. as a new member of the Board.
Dr. Lu previously served as the Executive Vice President and Chief Financial Officer of the Company from February 2012 to June 2017 and the President and Chief Executive Officer of the Company's subsidiary Avenue Therapeutics, Inc. ("Avenue") from July 2017 until March 2022. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. Additionally, Dr. Lu has served as a member of the Board of Directors of Veru, Inc. since 2021, a position she also held from 2016 to 2018, and has served as a member of the Board of Directors of Iventiva Healthcare Limited since 2018. From February 2007 through January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of the firm in February 2006. Dr. Lu holds an M.D. degree from the New York University School of Medicine and an M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science.
There were no arrangements or understandings between Ms. Lu and any other person pursuant to which she was elected as a director. Ms. Lu will receive compensation based on the same policies as the Company's other non-employee directors, which are described in the Company's definitive proxy statement filed with the SEC on May 2, 2022. In her role as Chief Executive Officer of Avenue, Ms. Lu received $1,082,129 in total compensation in 2021 and $1,052,962.17 in 2022. A press release related to Dr. Lu's appointment is attached as Exhibit 99.1 to this report and is incorporated by reference to this Item 5.02.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
Exhibit
Number
Description
10.1
​
Form of Indemnification Agreement (Lucy Lu)
99.1
​
Press release issued by Fortress Biotech, Inc., dated December 19, 2022.
104
​
Cover Page Interactive Data File (the cover page XBRL tags are imbedded in the Inline XBRL document)
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
Fortress Biotech, Inc.
​
(Registrant)
​
​
Date: December 19, 2022
​
​
​
By:
/s/ Lindsay A. Rosenwald, M.D.
Lindsay A. Rosenwald, M.D.
Chairman, President and Chief Executive Officer
​
​
​